Skip to content

the role of ncRNA derived from gastric cancer patients' blood in the gastric cancer diagnosis and prognosis

the role of ncRNA derived from gastric cancer patients' blood in the gastric cancer diagnosis and prognosis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-ROC-16010197
Enrollment
Unknown
Registered
2016-12-21
Start date
2016-12-20
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastric cancer

Interventions

A:peripheral venous blood of normal person
B:peripheral venous blood of gastric cancer patients
C:portal venous blood of gastric cancer patients

Sponsors

Shanghai General Hospital
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: 1. the criteria for gastric cancer: (1) aged 18 to 80 years old, no limitation in gender; (2) can endure the surgery and chemotherapy, and could survive more than 6 months; (3) undergo open operation; (4) patients have no other tumor; (5) no neoadjuvant chemotherapy before operation; (6) patients are volunteer to join in and sign the informed consent. 1.2 the criteria for normal people:1) aged 18 to 80 years old, no limitation in gender;2) No alcohol,tobacco, and other bad habits, living regularly;3)no other chronic disease, and no other acute disease recently.

Exclusion criteria

Exclusion criteria: 1) Pregnancy or breast-feeding women, older than 80 years old, the level of ECOG score is greater than or equal to 3; 2) liver,lung, supraclavicular lymph nodes,pelvic floor have metastasis or ovarian implant metastasis, Peritoneal dissemination; 3) having other digestive tract tumor history, including interstitialoma,sarcoid,lymphoma,carcinoid and so on; 4) having diseases of respiration, circulation, digestion, urinary tract etc.system ,and having high blood pressure with poor control, diabetes,mental disorders or disabled; 5) A large amount of ascites,cachexia; 6) have joined in other clinical trials within one months before hospitalization or are joining in; 7) Patients with poor compliance or consider the patients having poor compliance during the study.

Design outcomes

Primary

MeasureTime frame
ncRNA expression profile;

Countries

China

Contacts

Public ContactHuang Chen

Shanghai General Hospital

richard-hc@hotmail.com+86 13381758371

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026